Skip to Content

New Drug Approvals Archive - February 2019

See also: New Indications and Dosage Forms for February 2019

February 2019

Jeuveau (prabotulinumtoxinA-xvfs) Injection

Date of Approval: February 1, 2019
Company: Evolus, Inc.
Treatment for: Glabellar Lines

Jeuveau (prabotulinumtoxinA) is a proprietary 900 kDa purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar (frown) lines.

Cablivi (caplacizumab-yhdp) Injection

Date of Approval: February 6, 2019
Company: Ablynx NV
Treatment for: Acquired Thrombotic Thrombocytopenic Purpura

Cablivi (caplacizumab-yhdp) is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Egaten (triclabendazole) Tablets

Date of Approval: February 13, 2019
Company: Novartis
Treatment for: Fascioliasis

Egaten (triclabendazole) is a benzimidazole anthelmintic indicated for the treatment of fascioliasis, a neglected tropical disease (NTD) caused by liver flukes Fasciola hepatica and Fasciola gigantica.

Esperoct (turoctocog alfa pegol) Injection

Date of Approval: February 19, 2019
Company: Novo Nordisk
Treatment for: Hemophilia A

Esperoct (turoctocog alfa pegol, N8-GP) is an extended half-life factor VIII molecule for the treatment of adults and children with hemophilia A.

Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for Subcutaneous Injection

Date of Approval: February 28, 2019
Company: Genentech, Inc.
Treatment for: Breast Cancer

Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) is a combination of the approved HER2/neu receptor antagonist trastuzumab (Herceptin) and recombinant human hyaluronidase PH20 (an enzyme that helps to deliver trastuzumab under the skin) indicated for the treatment of HER2-overexpressing breast cancer.

Adhansia XR (methylphenidate hydrochloride) Extended-Release Capsules

Date of Approval: February 27, 2019
Company: Adlon Therapeutics L.P.
Treatment for: Attention-Deficit / Hyperactivity Disorder

Adhansia XR (methylphenidate hydrochloride) is an extended-release capsule formulation of the approved central nervous system (CNS) stimulant methylphenidate indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients six years and older.

New Drug Approvals Archive

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.